Table 14.3.1.1
Summary of TEAE by System Organ Class and Preferred Term
Safety Population

System Organ Class Preferred Term [a], n (%)	Placebo (N=XX)	Xanomeline Low Dose (N=XX)	Xanomeline High Dose (N=XX)
Number of subjects with at least one event	XX (XX.X)	XX (XX.X)	XX (XX.X)
<SOC 1>	XX (XX.X)	XX (XX.X)	XX (XX.X)
<Preferred Term 1>	XX (XX.X)	XX (XX.X)	XX (XX.X)
...	XX (XX.X)	XX (XX.X)	XX (XX.X)
<Preferred Term n>	XX (XX.X)	XX (XX.X)	XX (XX.X)
<SOC 2>	XX (XX.X)	XX (XX.X)	XX (XX.X)
<Preferred Term 1>	XX (XX.X)	XX (XX.X)	XX (XX.X)
...	XX (XX.X)	XX (XX.X)	XX (XX.X)
<Preferred Term n>	XX (XX.X)	XX (XX.X)	XX (XX.X)

Notes: TEAE=Treatment-Emergent Adverse Events.
Subjects are counted once within each system organ class and preferred term.
[a] All investigators adverse events were coded using MedDRA version xx.x.

Source dataset: adae, Generated on: DDMONYYYY:HH:MM
Program: <pid>.sas, Output: <pid><oid>.rtf, Generated on: DDMONYYYY:HH:MM